View all results
No results
News
Events
The industry
Industry overview
Industrial biotech
Swiss Biotech Report
Success Stories
Company directory
Jobs
Talent platform
Networking platforms
Newsletter
Association
Our mission
Members
Academy
Insight Events
Partners
Team
Media
Add listing
Log in
or
Register
0
Add listing
OZALIN
Product
prev
next
Leave a review
Bookmark
Share
Report
prev
next
Indicaton
Paediatric sedation prior to anaesthesia or procedures
Therapeutic indications
CNS
Type of product
Small molecule
Company
Primex Pharmaceuticals AG
Table
Phase
Marketed
Available in
EU
You may also be interested in
Dipraglurant (mGlu5 NAM) for PD-LID
Milestone: Indication under evaluation Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).
Featured
Phase II started
GABAb PAM for Chronic cough
We plan to develop our GABAB PAM drug candidate for the treatment of chronic cough. This target is clinically validated with baclofen, an orthosteric agonist of GABAB, is used off label to treat chronic cough patients. However, baclofen’s use is limited by serious side-effects, short half-life and gradual loss of efficacy during chronic treatment. By more precisely targeting the GABAB receptor with a PAM we aim to have a best-in-class treatment with improved tolerability suitable for the chronic nature of this disease. This indication has a significant unmet medical need and represents a solid commercial opportunity. We are in late clinical candidate selection phase and have demonstrated proof-of-concept in animal models of cough with several compounds. Subject to funding, we expect IND enabling studies to begin in 2024.
Featured
Discovery
GABAb PAM for Substance Use Disorder
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior has the right to select GABAB PAM drug candidates from our research program. We believe that substance use disorder is an indication with a significant commercial opportunity. Existing therapies often do not provide effective control of symptoms or have side effects that discourage adherence. Subject to regulatory approval, we believe that GABAB PAM may offer an innovative and differentiated treatment approach from existing therapies and may provide benefit to patients. We are in clinical candidate selection phase and expect IND enabling studies to be initiated in 2024. Indivior’s primary focus is substance use disorder, including alcohol use disorder.
Featured
Discovery
Cart
×
View all results
No results
Facebook
X
WhatsApp
Telegram
Pinterest
LinkedIn
Tumblr
Reddit
VKontakte
Mail
Copy link
Share via...
This site uses cookies:
Find out more.
Accept